


DSS30

Cat. No.:	HY-147387
CAS No.:	883027-32-5
Molecular Formula:	C ₁₆ H ₁₄ ClNO ₃ S ₂
Molecular Weight:	367.87
Target:	CDK; Amyloid-β
Pathway:	Cell Cycle/DNA Damage; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	DSS30 is a P25/CDK5 inhibitor that reduces β-amyloid (Aβ) secretion by inhibiting amyloid precursor protein lyase 1 (BACE1) phosphorylation. DSS30 can be used in the study of neurodegenerative diseases such as Alzheimer's disease ^[1] .								
In Vitro	<p>DSS30 (50 μM, 2 hours) inhibits the activity of the P25/CDK5 complex by up to 50% and the phosphorylation of BACE1 or Tau^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Expressed P25 PC12tet-off cell lines</td> </tr> <tr> <td>Concentration:</td> <td>50 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>8 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited BACE1 phosphorylation by 12%.</td> </tr> </table>	Cell Line:	Expressed P25 PC12tet-off cell lines	Concentration:	50 μM	Incubation Time:	8 hours	Result:	Inhibited BACE1 phosphorylation by 12%.
Cell Line:	Expressed P25 PC12tet-off cell lines								
Concentration:	50 μM								
Incubation Time:	8 hours								
Result:	Inhibited BACE1 phosphorylation by 12%.								

REFERENCES

[1]. Sul-Hee Chung, et al. Pharmaceutical composition comprising a p25/cdk5 inhibitor for preventing or treating a neurodegenerative disease. WO2006075808

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA